A Harvard Medical School affiliate is planning to retract six studies and correct 31 papers due to an ongoing investigation into several senior cancer researchers and administrators, according to The Wall Street Journal.
The investigation involves more than 50 papers, four of which are co-authored by Dana-Farber Cancer Institute CEO and President Dr. Laurie Glimcher, according to the WSJ. The institute has not determined whether research misconduct occurred, although several requests for retractions and corrections have been sent to journals.
Read More